Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma's stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to ... Read More